Issue navigation
Volume 6, Issue 3, May 2020
Editorial
Focus on subpopulations of atrial fibrillation patients
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 131–132, https://doi.org/10.1093/ehjcvp/pvaa034
Current Opinion
Speculation is not evidence: antihypertensive therapy and COVID-19
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 133–134, https://doi.org/10.1093/ehjcvp/pvaa021
Correspondence
Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 135–136, https://doi.org/10.1093/ehjcvp/pvaa028
Original article
Atrial fibrillation
Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 137–144, https://doi.org/10.1093/ehjcvp/pvz024
Editorial
Potassium homeostasis in patients with atrial fibrillation
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 145–146, https://doi.org/10.1093/ehjcvp/pvz034
Original article
Thrombosis and antithrombotic therapy
Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 147–154, https://doi.org/10.1093/ehjcvp/pvz035
Correspondence
Breaking the rules for studies using real-world observational data: the case of direct-acting anticoagulants and antiepileptic drugs
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 155–156, https://doi.org/10.1093/ehjcvp/pvz053
Response to the ‘Breaking the rules for studies using real-world observational data: the case of direct-acting anticoagulants and antiepileptic drugs by Dr Brown et al.’
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 157–158, https://doi.org/10.1093/ehjcvp/pvz054
Original article
Thrombosis and antithrombotic therapy
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 159–166, https://doi.org/10.1093/ehjcvp/pvz047
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 167–175, https://doi.org/10.1093/ehjcvp/pvz061
Disease management
Low quality of some generic cardiovascular medicinal products represents a matter for growing concern
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 176–187, https://doi.org/10.1093/ehjcvp/pvz037
Review
Hypertension
Resistant hypertension: new insights and therapeutic perspectives
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 188–193, https://doi.org/10.1093/ehjcvp/pvz057
Correspondence
Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists’ attitudes and practice
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 194–196, https://doi.org/10.1093/ehjcvp/pvz058
Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 197–198, https://doi.org/10.1093/ehjcvp/pvaa003
Vascular Ehlers–Danlos syndrome: can the beneficial effect of celiprolol be extrapolated to bisoprolol?
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 3, May 2020, Pages 199–200, https://doi.org/10.1093/ehjcvp/pvz067
